Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs on February 20, 2009, at a price of $32.55 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: February 20, 2009 (Notification date: February 23, 2009).
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.
- Price: $32.55 per ADR.
- Individuals Involved: Dr M M Slaoui (19 ADRs), Mr W C Louv (10 ADRs), and Dr D Pulman (16 ADRs).
- Financial Data: No financial performance metrics are included in this specific filing.